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ABSTRACT
Caloric restriction (CR) was recently demonstrated by us to restrict ovarian cancer 
growth in vivo. CR resulted in activation of energy regulating enzymes adenosine 
monophosphate activated kinase (AMPK) and sirtuin 1 (SIRT1) followed by downstream 
inhibition of Akt-mTOR. In the present study, we investigated the effects of metformin 
on ovarian cancer growth in mice fed a high energy diet (HED) and regular diet (RD) 
and compared them to those seen with CR in an immunocompetent isogeneic mouse 
model of ovarian cancer. Mice either on RD or HED diet bearing ovarian tumors were 
treated with 200 mg/kg metformin in drinking water. Metformin treatment in RD and 
HED mice resulted in a significant reduction in tumor burden in the peritoneum, liver, 
kidney, spleen and bowel accompanied by decreased levels of growth factors (IGF-1, 
insulin and leptin), inflammatory cytokines (MCP-1, IL-6) and VEGF in plasma and ascitic 
fluid, akin to the CR diet mice. Metformin resulted in activation of AMPK and SIRT1 and 
inhibition of pAkt and pmTOR, similar to CR. Thus metformin can closely mimic CR’s 
tumor suppressing effects by inducing similar metabolic changes, providing further 
evidence of its potential not only as a therapeutic drug but also as a preventive agent.
INTRODUCTION
Epithelial ovarian cancer affects more than 239 000 
women, with 152 000 deaths annually worldwide [1]. In 
2014, 21 980 women were estimated to be diagnosed with 
ovarian cancer and 14 270 died from this disease, making 
ovarian cancer the fifth leading cause of cancer death in 
women in the United States [2]. This high mortality rate is 
due to diagnosis at an advanced stage signifying widespread 
metastasis within the abdomen [3]. Cytoreductive 
surgery and chemotherapy with platinum and taxanes 
have increased the disease-free and overall survival, but 
recurrence of the disease is common in these patients [4].
Energy balance is defined as the balance between 
caloric intake and expenditure [5] and has been associated 
with the pathogenesis of various cancers. Caloric restriction 
(CR) has been demonstrated to attenuate tumorogenesis 
in various animal models [6]; on the other hand, a 
positive energy state and obesity has been demonstrated 
to be a contributing factor for multiple cancers including 
gynecological cancers, such as endometrium [7], ovary 
[8] and breast [9], as well as non-gynecological cancers, 
including pancreas [10], liver [11] and colon cancer [12]. In 
a previous study, we showed that a high energy diet (HED) 
was associated with extensive ovarian tumor formation, 
elevation of insulin, insulin growth factor (IGF-1) and higher 
levels of inflammation markers in an isogeneic mouse model 
of ovarian cancer. Conversely, CR diet exhibited less tumor 
burden with a significant reduction in levels of insulin, 
IGF-1 and inflammation markers [13]. The underlying 
biologic mechanisms of calorie intake and tumorogenic/
anti-tumorogenic effects are not fully understood, but 
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it has been shown to be associated with modulation of 
metabolic enzymes like adenosine monophosphate activated 
kinase (AMPK) and sirtuin 1 (SIRT1) [14, 15]. AMPK is 
a heterotrimeric serine/threonine protein kinase that acts 
as an ultrasensitive cellular energy sensor maintaining the 
energy balance within the cell [16] and has been shown to 
have a role in inhibiting the proliferation of tumor cells [17]. 
AMPK performs its anti-tumorogenic activity in multiple 
ways including cell cycle arrest associated with stabilization 
of p53 and cyclin-dependent kinase inhibitors [18–20] and 
inhibition of cell growth by suppressing the synthesis of 
cellular macromolecules, including fatty acids, triglycerides, 
cholesterol, glycogen, ribosomal RNA and proteins [21, 
22]. Mechanistically, AMPK inhibits the pro-oncogenic 
mammalian target of rapamycin complex (mTOR) [16, 23] 
and thus hampers the translation of many proteins essential 
for rapid cell growth. Indirect effects of AMPK results in 
attenuation of the insulin/IGF-1 pathways, which are known 
to be upregulated in many cancers including ovarian cancer 
[17]. SIRT1 is a nicotinamide adenine dinucleotide (NAD+)-
dependent histone deacetylase involved in the cell’s stress 
adaption systems, DNA damage repair, cell metabolism and 
survival [24, 25]. In mammals, SIRT1 expression, has been 
shown to be induced by CR [15] and delay age and associated 
diseases, such as cancer, atherosclerosis and diabetes [26–29].
Metformin is a member of the biguanide class of 
antihyperglycemic agents and has been recently revealed 
to have anti-tumorogenic effects [30, 31]. Metformin 
decreases hepatic glucogenesis, increases insulin sensitivity, 
enhances peripheral glucose uptake, and decreases glucose 
absorption from the gastrointestinal tract [32]. On the 
cellular level, metformin inhibits mitochondrial complex 1, 
which interferes with oxidative phosphorylation, resulting 
in decreased adenosine triphosphate (ATP) production 
and energetic stress [33]. Epidemiologic studies have 
shown that metformin lowers cancer risk and improves 
cancer outcomes in diabetic patients when compared with 
patients treated with other types of antihyperglycemic 
agents [34, 35]. Therefore, metformin has been repurposed 
as therapy in gynecologic and non-gynecologic cancers 
[36] and is currently being evaluated in various clinical 
trials [36]. The most evaluated mechanism of metformin’s 
antihyperglycemia and anti-tumor activity is the activation 
of AMPK [36]. Metformin has also been demonstrated to 
induce SIRT1 levels in hepatic cancer lines [24].
In this study, we investigated the downstream 
effects of metformin on ovarian cancer growth using 
immunocompetent mouse model under nutritional excess as 
well as regular balanced dietary conditions and its similarity 
with tumor inhibitory effects of CR to observe if metformin 
can be utilized in lieu of CR to limit ovarian cancer growth.
RESULTS
Metformin decreases the tumor burden and 
ascites volume
To investigate if metformin can reduce tumor 
progression similar to CR, a set of HED and regular diet 
(RD) fed mice were given metformin daily in drinking water 
7 days after tumor implantation. As previously reported 
[13], mice on HED had highest weight gain while the CR 
diet (CRD) mice maintained their weight (Figure 1A). 
Metformin intake did not significantly affect the weight gain 
of HED or RD mice (Figure 1A), which was also reflected 
in the end weights at the time of the sacrifice (Figure 1B). 
Metformin treatment significantly reduced the ascites 
accumulation in both RD and HED groups, but the highest 
reduction was observed in the CRD group (Figure 1C). 
Metformin treatment of the HED group was most effective 
in reducing the tumor progression with significant reduction 
of tumor burden in the peritoneum, diaphragm, bowel, 
liver, kidney and spleen (Figure 2A–2F). In the RD group, 
metformin reduced the tumor burden at the bowel, liver, 
kidney and spleen. CRD group had the lowest tumor burden 
at all organ sites (Figure 2A–2F). The hemotoxylin and 
eosin evaluation of the tumor sections also showed reduced 
tumor nodules at the diaphragm, peritoneum and adipose 
Figure 1: Metformin (Met) decreases the tumor burden and ascites volume. Mouse ovarian tumors were generated by injecting 
ID8 cells in mice fed a RD, a HED and a CRD. A subset of RD and HED fed mice were treated with Met for the study period. (A) Average 
weight progression of mice per group is presented as percentage increase in weight with the average starting weight taken as 100%. (B) 
Weight at the time of sacrifice (70 days post-tumor injection). (C) Ascites volume as measured after collection at time of sacrifice. ***p < 
0.001, **p < 0.01, ns = non-significant. CRD, caloric restriction diet; HED, high energy diet; RD, regular diet.
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tissue (Figure 3A–3C) with metformin treatment in both 
HED and RD groups, akin to CRD group. This was also 
reflected in the decreased number of positive Ki-67 stained 
cells observed in tumors from CRD and metformin treated 
groups, quantified as Ki-67 index (Figure 3D). Overall, our 
data showed that metformin decreased the ascites and tumor 
burden in both the RD and HED groups significantly, similar 
to CRD. However, the tumor reduction by metformin in 
HED group was more pronounced than the tumor reduction 
observed in the RD treatment group.
Metformin regulates the levels of hormones 
controlling the energy balance
Growth hormones including insulin, IGF-1, leptin 
and adinopectin that regulate energy metabolism were 
estimated under metformin treatments in plasma and 
ascites fluid of the mice. Metformin was most efficient 
in reducing the levels of insulin, IGF-1 and leptin in both 
the plasma and ascites of the HED group (Figure 4A–4C). 
Adiponectin was significantly increased in the plasma 
but not in the ascites by metformin in the HED mice 
(Figure 4D). Metformin decreased IGF-1 and leptin 
levels significantly in both the plasma and ascites of the 
RD group, while insulin was reduced only in the ascites 
(Figure 4A–4C). Adiponectin was significantly increased 
in the plasma but not in the ascites by metformin in the RD 
mice (Figure 4D). CRD mice still had the lowest levels 
of IGF-1, insulin and leptin and increased adiponectin 
as observed previously [13]. In general, HED fed mice 
showed a tumor promoting environment while mice on 
CRD showed the inverse profile. Metformin reversed most 
of these tumor promoting effects of diet in HED and RD, 
similar to the CRD group; however, CRD was the most 
Figure 2: Metformin (Met) reduces the clinical ovarian tumor score. At the end of the study, various organs of each mouse 
from the RD, HED and CRD untreated and Met treated groups were grossly examined for enumeration of visible tumor nodules. Score was 
stipulated as 0: no nodule; 1: 1 nodule; 2: 2 to 5 nodules and 3: more than 5 nodules observed per organ. Tumor scoring at (A) Peritoneum, 
(B) Diaphragm, (C) Bowel, (D) Liver, (E) Kidney, and (F) Spleen are shown. ***p < 0.001, **p < 0.01, *p < 0.05, ns = non-significant. 
CRD, caloric restriction diet; HED, high energy diet; RD, regular diet.
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effective in maintaining the lowest levels of all growth 
factors and hormones.
Metformin decreased the inflammatory 
markers and angiogenic factors
The role of inflammatory molecules (monocyte 
chemoattractant protein-1 [MCP-1] and interleukin 6 
[IL-6]) and angiogenic factors (vascular endothelial 
growth factor [VEGF]) in ovarian tumorogenesis is 
well established [37, 38], and the inhibition of these 
markers by CRD has been recently demonstrated [13]. As 
observed with growth factor levels, metformin had more 
pronounced inhibition of these factors in HED group 
compared to the RD group. Excluding plasma VEGF 
(Figure 5Ci), the levels of MCP-1, IL-6 and VEGF were 
significantly reduced by metformin (Figure 5A, 5B, 5Cii). 
Metformin did not reduce IL-6 and VEGF in the plasma 
of RD mice but significantly reduced MCP-1 (Figure 
5Ai, Bi, 5Ci), while all 3 were significantly inhibited in 
the ascitic fluid (Figure 5Aii, 5Bii, 5Cii). The CRD group 
had lower levels of MCP-1, IL-6 and VEGF compared 
to the HED and RD groups. Interestingly, metformin 
decreased MCP-1 and VEGF levels in the ascites of the 
RD and HED groups more significantly than CR (Figure 
5Aii, 5Cii). Based on these results, it can be suggested 
that metformin significantly alters the inflammatory and 
angiogenic armamentarium of ovarian cancer cells, even 
under the conditions of rich nutrition.
Metformin induced AMPK and SIRT1
AMPK and SIRT are 2 enzymes involved in 
regulation of energy metabolism and reported to mediate 
the positive effects of CR [16, 25]. The CRD group 
showed the strongest activation of phosphorylated acetyl-
CoA carboxylase (pACC), a surrogate marker for AMPK 
activation, while HED groups demonstrated almost no 
phosphorylation of ACC as reported before [13] (Figure 
6A, 6B). Metformin increased the pACC expression 
significantly in RD and HED groups in both peritoneal and 
adipose tumor tissue. A similar pattern was also observed 
for SIRT1 expression in the tumor tissues (Figure 6D, 
6E). Metformin treatment also activated AMPK and 
SIRT1 in the liver, which was also associated with the 
amelioration of the hepatic steatosis observed in the HED 
group (Figure 6C, 6F). The quantification of the staining 
intensity is represented as bar graphs (0–1: no or weak stain; 
2: moderate stain and 3: strong stain), respective of each 
panel. Taken together, these results suggest that metformin 
Figure 3: Metformin (Met) decreases the ovarian tumor growth. Paraffin tumor sections obtained from the peritoneum (A), 
diaphragm (B), peritoneum and adipose were stained with hemotoxylin and eosin and visualized under a bright-field (20x) to observe for 
tumor nodules. Each stained tissue picture is a representative of at least 5 individual mouse sections from each of the RD, HED, CRD and 
Met treated groups. (D) Representative Ki-67 staining from the ID8 tumors at the peritoneum (200x). Count of positive Ki-67 cells from 5 
high powered fields (x400) in 3 different xenografts from each group is presented as bar graph. ***p < 0.001, ns = non-significant. CRD, 
caloric restriction diet; HED, high energy diet; RD, regular diet; Unt, untreated.
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activated AMPK and increased the expression of SIRT1 
significantly, parallel to CRD both in the tumor and in the 
host tissue.
pAkt and p-mTOR expression were inhibited 
by metformin
Phosphorylated protein kinase B (pAkt) and 
phosphorylated mTOR (p-mTOR), are the 2 common 
downstream signaling molecules for action of CRD, 
AMPK and SIRT1 [21, 36, 39–41]. CRD mice had the 
lowest and HED and RD mice had the highest expression 
of pAkt (Figure 7A, 7B) and p-mTOR (Figure 7C, 7D) 
as reported previously [13]. Metformin treatment reduced 
both pAkt and p-mTOR expression in HED and RD 
groups in the peritoneal and adipose tissue, similar to 
CRD (Figure 7A–7D). The quantification of the staining 
intensity is represented as bar graphs. This demonstrates 
that metformin modulated common oncogenic factors with 
CR, even under HED conditions.
Figure 4: Metformin (Met) regulates the levels of hormones controlling the energy balance. Plasma and ascitic fluid collected 
from ovarian tumor bearing mice (n = 6) on RD, HED, and CRD and Met on day 70 were subjected to enzyme-linked immunosorbent assay 
to determine the levels of (Ai, ii) IGF-1, (Bi, ii) insulin, (Ci, ii) leptin and (Di, ii) adiponectin. ***p < 0.001, **p < 0.01, *p < 0.05, ns= 
non-significant. CRD, caloric restriction diet; HED, high energy diet; IGF, insulin growth factor; RD, regular diet.
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DISCUSSION
Our study shows that the levels of caloric intake 
have significant effects on ovarian cancer growth and these 
effects can be modulated by metformin. We revalidate that 
the positive energy balance provided by HED aggravates 
ovarian cancer by creating an environment that encourages 
cancer growth, while a negative energy balance achieved 
by 30% CR modulated the progression of ovarian tumors 
in mice. Here, we have demonstrated that metformin 
inhibits ovarian cancer growth by reorganizing the tumor 
promoting parameters under a high energy state in a 
similar manner as that achieved by a CRD.
Obesity has been suggested to be a prognostic 
factor for ovarian cancer. Having a body mass index 
of more than 35 is associated with an increased risk of 
mortality in ovarian cancer patients with a relative risk 
of 1.5 [8]. In another study, being overweight or obese 
in early adulthood is associated with a higher mortality 
among patients with ovarian cancer [42]. Metformin 
intake has been shown to decrease ovarian cancer risk in 
diabetic patients [43], increase progression free survival 
Figure 5: Metformin (Met) decreased the inflammatory markers and angiogenic factors. Plasma and ascitic fluid collected 
from ovarian tumor bearing mice (n = 6) on RD, HED, and CRD and Met on day 70 were subjected to enzyme-linked immunosorbent assay 
to determine the levels of (Ai, ii) MCP-1, (Bi, ii) IL-6 and (Ci, ii) VEGF. ***p < 0.001, **p < 0.01, *p < 0.05, ns = non-significant. CRD, 
caloric restriction diet; HED, high energy diet; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein-1; RD, regular diet; VEGF, 
vascular endothelial growth factor.
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Figure 6: Metformin (Met) induced AMPK and SIRT1. Paraffin tumor sections obtained from the peritoneum and adipose sites 
and liver of mice from the RD, HED, and CRD groups with and without Met treatment were immunostained with antibodies against 
phosphorylated acetyl-CoA carboxylase (pACC), as a marker for AMPK activation (A, B, C) (Continued ).
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Figure 6: (Continued ) Metformin (Met) induced AMPK and SIRT1. and SIRT1 (D, E, F). Stains were developed using 
chromogen and visualized under a bright-field (200x) to observe for positive brown stain indicative of expression. Each stained tissue 
picture is a representative of at least 5 different fields examined per section from a minimum of 3 individual stained sections per group. 
Quantification of the intensity of the stain was performed on a scale of 0–3: 0–1 for no or weak stain; 2 for moderate stain and 3 for strong 
stain from 3 different fields of a minimum of 2 stained sections and is represented as a bar graph. ***p < 0.001, **p < 0.01, *p < 0.05, 
ns = non-significant. AMPK, adenosine monophosphate activated kinase; CRD, caloric restriction diet; HED, high energy diet; RD, regular 
diet; SIRT1, sirtuin 1; Unt, untreated.
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[44] and overall survival in women with ovarian cancer 
[45]. While there are likely more than one mechanism for 
these improved outcomes and inhibition of ovarian cancer 
tumorogenesis, one of the mechanisms might be the 
regulation of deranged host energy balance by metformin 
related to adiposity, deregulated insulin-IGF-1 pathway or 
chronic inflammation, which is often observed in diabetic 
and cancer patients [46]. Increased energy balance, which 
culminates in increased adiposity, changes the levels of 
hormones such as insulin, adiponectin, leptin and IGF-
1 [47], which is also associated with cancer including 
ovarian [48, 49]. Insulin has tumor-enhancing effects and 
exerts these effects directly via insulin or indirectly via 
IGF-1 receptors on preneoplastic and neoplastic cells or 
other growth receptors [50], most frequently resulting 
in activation of the P13K/Akt-mTOR pathway, a central 
regulator of cell growth, proliferation and survival [6, 
51, 52]. On the other hand, decreased adiponectin level 
has been associated with the development of colorectal 
[53], endometrium [54] and breast cancer [55]. Metformin 
modifies these hormones and growth factor levels in 
ovarian cancer-bearing mice fed HED or RD, which could 
ultimately decrease the tumor burden. An interesting 
observation is that metformin was the most efficient in 
reducing insulin and IGF-1 levels in the HED group, 
consistent with the highest tumor reduction by metformin 
observed in the HED group. This might be secondary to 
the fact that HED caused the most significant metabolic 
and hormonal derangements, and metformin might be 
more effective in a milieu where these derangements are 
more profound, as opposed to RD. Similarly, metformin 
also showed reduction in IL-6, MCP-1 and VEGF 
levels, important factors shown to promote ovarian 
tumor progression [56–60]. MCP-1 was reduced most 
Figure 7: Metformin (Met) inhibited pAKT and pmTOR. Paraffin tumor sections obtained from the peritoneum and adipose sites 
of mice from the RD, HED and CRD groups with and without Met treatment were immunostained with antibodies against phosphorylayed 
protein kinase B (pAkt) (A, B) and mammalian target of rapamycin (p-mTOR) (Continued ). 
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significantly by metformin, which was also observed in 
our previous study, where metformin negated the effect of 
adipocyte mediated MCP-1 production [61].
PI3K/Akt-mTOR pathway, one of the most 
upregulated pathway observed in ovarian and other 
cancers, is also the common downstream pathway 
implicated in growth factor signaling and CR [62–64]. 
Akt stimulates the cell cycle progression, cell survival and 
inhibits apoptosis [63, 65]. mTOR is a nutrition regulated 
serine/threonine protein kinase that is activated by the Akt 
pathway but is inhibited by AMPK [66–68]. AMPK is 
a serine/threonine protein kinase that acts as a sensor of 
cellular energy status and is regulated by the AMP:ATP 
levels [69]. Recent evidence suggests that AMPK also 
regulates cell proliferation, cell growth, and autophagy 
[70]. Our current and previous data showed that CR diet 
increases AMPK activation along with decreased Akt 
and mTOR activation. The same was achieved in the 
HED and RD groups with metformin treatment. This is 
consistent with previous studies that have demonstrated 
that under nutrient-deprived conditions, which result 
in energy depletion, AMPK is activated and transmits 
Figure 7: (Continued ) Metformin (Met) inhibited pAKT and pmTOR. (C, D). Stains were developed using chromogen and 
visualized under a bright-field (200x) to observe for positive brown stain indicative of expression. Each stained section is a representative 
of at least 5 different fields examined per section from a minimum of 3 individual stained sections per group. Quantification of the intensity 
of the stain was performed on a scale of 0–3: 0–1 for no or weak stain; 2 for moderate stain and 3 for strong stain from 3 different fields of 
minimum of 2 stained sections and is represented as a bar graph. ***p < 0.001, **p < 0.01, *p < 0.05, ns = non-significant. AMPK, adenosine 
monophosphate activated kinase; CRD, caloric restriction diet; HED, high energy diet; RD, regular diet; SIRT1, sirtuin 1; Unt, untreated.
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energetic stress signals to mTOR via tuberous sclerosis 2 
and raptor, which ultimately inhibit mTOR activity [71]. 
SIRT1, another energy regulating enzyme, mediates the 
longevity conferred by CR [15, 72]. SIRT1 also regulates 
IGF-1, adiponectin and insulin levels in various tissues 
[73]. In cancer pathogenesis; SIRT1 plays a bivalent role; 
functional loss of SIRT1 promotes tumorogenesis because 
of genomic instability [25]. However, SIRT1 has also 
been associated with survival and proliferation of tumors 
such as breast [74], gastric [75] and prostate cancer [76]. 
Metformin treatment increased SIRT1 expression in RD 
and HED groups similar to the expression increased by 
CRD. Molecular mechanism of regulation and interaction 
of both these energy sensors has yet to be elucidated, but 
recent data have shed a light on the interaction between the 
AMPK and SIRT pathway [77, 78]. NAD+ synthesis has 
been claimed to be a cellular mechanism to increase sirtuin 
activity [77]. For instance, activation of hepatic AMPK by 
metformin induces increased expression of nicotinamide 
phosphoribosyltransferase, which increases intracellular 
NAD+/NADH ratio and ultimately activates SIRT1 [78]. 
On the other hand, AMPK does not affect the nicotinamide 
phosphoribosyltransferase enzyme in endothelial cells 
[79], which suggests that AMPK and SIRT1 use different 
interaction pathways in various tissues. To better 
understand the communication mechanisms between these 
2 energy sensors in different types of tissues and different 
types of malignancies, more research is required.
By modulating the dietary intake, we modulated the 
host metabolism and consequently the host environment, 
which had a significant effect on ovarian cancer 
progression. This was demonstrated by the presence of 
hepatic steatosis or deposition of fat within hepatocytes, 
which is mostly prevalent in obese populations [80]. 
Hyperinsulinemia also contributes to hepatic steatosis 
by increasing the expression of lipogenic enzymes and 
diminishing fatty-acid oxidation [81]. We observed that 
metformin ameliorates hepatic steatosis in the HED 
liver, along with an increased expression of pACC and 
SIRT1 (Figure 6C), a finding which is consistent with 
previous studies [78–80]. AMPK also shows anti-
lipogenic activity by suppressing lipogenic enzymes 
(acetyl-CoA carboxylase, HMGCoA reductase, etc.) [82] 
and lipogenesis transcription factors (sterol regulatory 
element-binding proteins and carbohydrate response 
element binding protein), which subsequently decreases 
lipid accumulation [81].
CR is strongly linked to retarding both cancer and 
aging, which share many common cellular and molecular 
mechanisms [83]. The insulin-IGF-1 growth factor nexus 
and inflammatory cytokines involved in both pathologies 
converge down to activate mTOR, which is inhibited 
both by CRD and metformin [83, 84]. mTOR is known 
to orchestrate the process of ‘geroconversion’, whereby 
it places a cell into senescence [85]. Inhibition of mTOR 
by rapamycin or its analogs has been shown to prevent 
both cancer and aging in various models [23, 86, 87]. 
This mTOR driven senescence can result in a selective 
survival advantage to cancer cells [83]. We examined 
mTOR mediated senescence in our model system by 
staining for ɣH2A.X, a known senescence biomarker 
[88, 89]. Nuclear expression of ɣH2A.X represents DNA 
damage associated with aging [88]. We could only detect 
its limited expression in HED tumors, while hardly any 
expression was seen in tumor tissue of RD and none 
was detected in CRD tumor tissue (Supplementary 
Figure S1). This indicates that HED, which resulted in 
hyperinsulinemia and increased activation of p-mTOR, 
could also trigger senescence in cancer cells harbored by 
the host. Further studies are required to delineate the exact 
role of mTOR driven senescence under high energy or CR 
environments in the tumor cells. Presently, the relationship 
between senescence and cancer is very complex as cellular 
senescence also serves to block tumorigenesis [90].
In summary, there are multiple pathways involved 
in ovarian cancer pathogenesis which metformin 
successfully modifies, resulting in decreased tumor 
formation and spread in a manner very similar to CR 
(Figure 8). Interestingly, metformin had a more significant 
effect in the high energy background suggesting an 
ability of metformin to be more effective in an increased 
metabolically deranged tumor environment. Our study also 
suggests that metformin has an effect not only on the tumor 
environment but also on modulating the host environment 
by making it less conducive for tumor growth, quite similar 
to CR. Metformin may have utilization as a CR mimetic 
to ameliorate aggressive tumor growth, as implementation 
of CR in already debilitated cancer patients may not be 
feasible. Our results strongly support future clinical 
utilization of metformin as both a repurposing drug for 
the treatment of ovarian cancer and also as a potential 
preventative agent for select populations.
METHODS
Tissue culture
Dr. Keith Knutson (Vaccine & Gene Therapy 
Institute of Florida, Port Saint Lucie, FL) donated ID8 
mouse ovarian cancer cells, and they were tested for 
absence of standard mouse pathogen panel (Missouri 
University Research Animal Diagnostic Laboratory; 
Columbia, MO). We maintained ID8 cells in Rosewell 
Park Memorial Institute media, which was purchased from 
HyClone-ThermoScientific (Waltham, MA) containing 
10% (v/v) fetal bovine serum (BioAbChem, Ladson, SC).
Animal studies
All animal experiments were performed according to 
an Institutional Animal Care and Use Committee of Henry 
Ford Health Systems approved protocol, and institutional 
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guidelines for the proper and humane use of animals 
in research were followed. Our facility is approved by 
the Association for Assessment and Accreditation of 
Laboratory Animal Care. C57B6 mice were purchased 
from Jackson Laboratories (Bar Harbor, ME).
Mouse diet
We purchased various mouse diets from Bioserv 
(Frenchtown, NJ). The mice groups were fed on purified RD 
or nutritionally balanced HED with 60% kilocalories from 
fat (35.7% carbohydrate; 20.5% protein) or 30% nutritionally 
supplemented CRD as described before [91, 92].
Tumor generation
Six-week-old female C57B6 mice were weighed 
and randomized into the 3 dietary treatment groups as 
described above: (1) RD (n = 20), (2) HED (n = 20) and 
(3) CRD (n = 10). Mice were weighed twice a week. After 
30 days of respective diet, 5 x 106 ID-8 mouse ovarian 
cancer cells in 200 μl phosphate-buffered saline were 
injected into the peritoneal cavity of the mice [13]. Post-7 
days of tumor implantation, 1 set of mice from the RD 
and HED groups (n = 10) was given 200 mg/body weight 
metformin in water [93] daily, till the end of the study. 
The mice were monitored daily for any discomfort and 
weighed twice a week. The diet regimens were continued 
for another 60 days, after which the mice were sacrificed 
and autopsied. Ascitic fluid, blood, tumor tissue and vital 
organs were collected from each mouse.
Tumor score
Tumor nodules morphology and count were 
identified grossly at the liver, spleen, kidneys, bowel, 
peritoneum and diaphragm. A scoring system to identify 
the tumor burden in every organ was used as 0: no nodule 
observed; 1: 1 nodule observed; 2: 2 to 5 nodules and 3: 
more than 5 nodules observed per organ [13]. Scoring was 
performed in a blinded manner by 2 individuals including 
a gynecology oncology fellow (ZW).
Enzyme-linked immunosorbent assay (ELISA)
Levels of leptin, adiponectin, insulin, IGF-1, IL-
6, VEGF and MCP-1 were estimated by enzyme-linked 
immunosorbent assay (ELISA) in plasma and ascitic 
Figure 8: Proposed mechanism of metformin effect on ovarian cancer. Metformin and CR act in a similar manner to curtail 
ovarian cancer growth, while HED aggravates ovarian cancer. Both metformin and CR result in activation of AMPK and SIRT1. SIRT1 
activation could occur independently or as a consequence of AMPK activation. Activation of these metabolic enzymes is linked to reduction 
in growth factors and hormones like insulin, IGF-1 and leptin, which leads to inhibition in the protein kinase B-mammalian target of 
rapamycin (Akt-mTOR) pathway activation resulting in decreased ovarian tumor growth. Inhibition of cytokines like MCP-1 and IL-6 and 
the angiogenic factor VEGF reduces inflammation and angiogenesis, which also leads to limited ovarian tumor growth. Overall, metformin 
and CR have very similar effects in modulating the deranged tumor environment milieu and in effect restricts ovarian cancer progression. 
AMPK, adenosine monophosphate activated kinase; CR, caloric restriction; HED, high energy diet; IGF-1, insulin growth factor 1; IL-6, 
interleukin 6; MCP-1, monocyte chemoattractant protein-1; SIRT1, sirtuin 1; VEGF, vascular endothelial growth factor.
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fluid. The insulin ELISA was purchased from Millipore 
(Billerica, MA) and all other kits were from R&D System 
(Minneapolis, MN). The ELISAs were carried out 
according to the manufacturers’ instructions.
Immunohistochemistry
After excising the tumor tissues and other 
organ tissue from mice, specimens were fixed in 10% 
formaldehyde for 48 hours and paraffin-embedded. 
Consecutive sections of 4 micron thick were cut 
and processed for hematoxylin and eosin staining; 
immunohistochemistry for pACC (cat. no. 3661, used 
at 1:100), p-mTOR (cat. No: 2976, used at 1:50), pAkt 
(Ser473, cat. No: 4060 used at 1:50), SIRT1 (cat no: 
15404, used at 1:100) and Ki-67 (cat. No: ab15580, 
used at 1:100), ɣH2A.X (cat no:9718, used at 1:100). 
Antibodies to pACC, p-mTOR, pAkt, and ɣH2A.X 
were from Cell Signaling Technology (Denver, MA). 
Ki-67 was from Abcam (Cambridge, MA). p16 was 
from Proteintech (cat. No: 10883–1-AP, used at 1:200; 
Proteintech Group, Chicago, IL). SIRT1 was from Santa 
Cruz Biotech (Santa Cruz, CA). Solutions obtained 
from Dako Cytomation (Carpinteria, CA) were used for 
performing immunostaining as described before [13, 93]. 
The slides were examined under a light microscope, and 
representative pictures were taken from a minimum of 3 
slides of each group [93]. The quantification of the stain 
intensity was performed by assigning a score of 0–1 for 
no or weak stain; 2 for moderate stain and 3 for strong 
stain. All slides were examined in a blinded manner by 2 
individuals, including a pathologist (RA).
Statistical analysis
Data were statistically analyzed using the Graph Pad 
Prism software (GraphPad Software Inc, La Jolla, CA) using 
a combination of t-test and analysis of variance methods.
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